DOCSLIB.ORG

United States Patent ( 10 ) Patent No.: US 10,463,648 B2 Benjamin Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
United States Patent ( 10 ) Patent No.: US 10,463,648 B2 Benjamin Et Al US010463648B2 United States Patent ( 10 ) Patent No.: US 10,463,648 B2 Benjamin et al. (45 ) Date of Patent : * Nov . 5 , 2019 (54 ) SUSTAINED RELEASE PHARMACEUTICAL 5,756,532 A 5/1998 Stack et al . COMPOSITIONS 5,914,263 A 6/1999 Buizer et al . 5,962,465 A 10/1999 Stack et al . 6,010,718 A 1/2000 Al- Razzak et al. 6,126,970 A 10/2000 van ' t Klooster ( 71) Applicant: Wyeth LLC , Madison , NJ (US ) 6,218,405 B1 4/2001 Birch et al . 6,350,773 B1 2/2002 Marquis 6,417,177 B1 7/2002 Nelson (72 ) Inventors : Eric Joel Benjamin , Jamestown , NC 6,524,618 B1 2/2003 Kumar et al . (US ) ; Wendy Ann Dulin , Tuxedo , NY 7,135,479 B2 11/2006 Zhou et al . 7,662,979 B2 2/2010 Galante (US ) ; Yanning Lin , Lake Hiawatha , NJ 2001/0008903 A1 7/2001 Birch et al. (US ) ; Kai Zhuang , River Edge, NJ 2002/0114836 A1 8/2002 Maillard (US ) 2005/0095292 Al 5/2005 Benjamin et al . 2007/0190129 Al 8/2007 Ahmed et al. ( 73 ) Assignee : Wyeth , LLC , Wilmington , DE (US ) 2018/0193311 Al 7/2018 Benjamin et al. FOREIGN PATENT DOCUMENTS ( * ) Notice : Subject to any disclaimer , the term of this patent is extended or adjusted under 35 AU 2004/286855 4/2011 CN 1155546 7/1997 U.S.C. 154 ( b ) by 0 days . EP 0771800 A2 5/1997 This patent is subject to a terminal dis JP HO2-003608 1/1990 claimer . JP H09-249671 9/1997 JP H09-315969 12/1997 JP H11-509539 8/1999 ( 21) Appl. No .: 16 /058,769 WO WO 1991/13872 A1 9/1991 WO WO 1997/003670 2/1997 ( 22 ) Filed : Aug. 8 , 2018 (Continued ) (65 ) Prior Publication Data OTHER PUBLICATIONS US 2018/0344695 A1 Dec. 6 , 2018 Application Technology of Pharmaceutically Used Auxiliary Mate Related U.S. Application Data rials, 2nd Ed. , Huimin Hou et al. , Chinese Medical Technology ( 60 ) Continuation of application No. 15/ 912,438 , filed on Publishing House , Beijing, 2002, p . 200-204 and p . 209-212 . Mar. 5 , 2018 , now Pat . No. 10,292,966 , which is a (Continued ) division of application No. 10 /975,254 , filed on Oct. 28 , 2004 , now abandoned . Primary Examiner Michael G. Hartley (60 ) Provisional application No.60 /515,315 , filed on Oct. Assistant Examiner Leah H Schlientz 29 , 2003 . ( 74 ) Attorney , Agent, or Firm — Knobbe , Martens, Olson & Bear LLP ( 51 ) Int . Cl. A61K 31/407 ( 2006.01 ) A61K 9/20 ( 2006.01 ) ( 57 ) ABSTRACT A61K 9/28 ( 2006.01 ) (52 ) U.S. CI. The present invention provides controlled release dosage CPC A61K 31/407 ( 2013.01 ) ; A61K 9/2054 formulations of compounds having the Formula : (2013.01 ) ; A61K 9/2866 (2013.01 ) ( 58 ) Field of Classification Search CPC A61K 9/2054 ; A61K 31/407 ; A61K 9/2866 R3 See application file for complete search history . R4 ( 56 ) References Cited HN ( CH2) n - Z U.S. PATENT DOCUMENTS -R2 4,988,679 A 1/1991 Chavkin et al. Ri 5,009,895 A 4/1991 Lui 5,028,434 A 7/1991 Barclay et al. 5,112,621 A 5/1992 Stevens et al . 5,126,366 A 6/1992 Stack et al . or pharmaceutically acceptable salts thereof, and in particu 5,166,367 A 11/1992 Stack et al. lar , aplindore . The dosage forms are useful, inter alia , for 5,189,171 A 2/1993 Stack et al. 5,225,206 A 7/1993 Fushimi et al . reducing side effects from administration of such com 5,235,055 A 8/1993 Stack et al. pounds. 5,245,051 A 9/1993 Stack et al. 5,318,988 A 6/1994 Schohe -Loop et al. 5,633,376 A 5/1997 Thurkauf et al . 28 Claims, No Drawings US 10,463,648 B2 Page 2 ( 56 ) References Cited Human Pharmacology : Molecular to Clinical , K. Kist , ed . (Mosby Year Books: Philadelphia ) 1991. Ishii et al . , Structure and Synthesis of Arnottin I : a FOREIGN PATENT DOCUMENTS 6H -Benzo [d ] naphtho [ 1.2 -b ] pyran - 6 - one Derivative from a Plant Source , J Chem Soc - Perkin Transactions 1 , ( 1993 ) 9 : 1019-1022 . WO WO 1998/29415 7/1998 Lindenmayer et al. , New pharmacotherapeutic modalities for nega WO WO 1998/43646 10/1998 tive symptoms in psychosis . Acta Psychiatrica Scand. , ( 1995 ) 92 WO WO 2001/41750 A2 6/2001 (Supp . 388 ) : 15-19 . WO WO 2005/044262 5/2005 Keith , S., Advances in psychotropic formulations, Prog Neuropsychopharmacol Biol Psychiatry (2006 ) 30 (6 ): 996-1008 . OTHER PUBLICATIONS Ennis et al. , Novel indolodioxanes with antihypertensive effects : potent ligands for the 5 -HT1A receptor. J Med Chem . ( 1992 ) Applied Pharmacokinetics Principles of Therapeutic Drug Moni 35 ( 16 ) : 3058-3066 . toring , William J. Jusko , “ Guidelines for Collection and Analysis of Principles of Drug Action : The Basis of Pharmacology , 3rd ., W.B. Pratt & P. Taylor, eds. , ( Churchill Livingstone : New York ) 1990 . Pharmacokinetic Data , ” ( 1992 ) Ch . 2 , pp . 2-1 through 2-43 . Remington's Pharmaceutical Sciences , 18th Ed ., Gennaro , ed ., Bagul et al. , Current Status of Tablet Disintegrants : A Review , (Mack Publishing Co., Easton , PA ) 1990 . ( 1996 ) 1-9 , at http://www.pharmainfo.net/exclusive/reviews/current_ Remington : The Science and Practice of Pharmacy , 20th edition , status_of_tablet_disintergrants : a_review / . chapter 47 , pp . 1047-1060 , 2000 . Cheng et al ., Schizophrenia and drug delivery systems, J Drug Svensson et al. , Partial dopamine receptor agonists reverse behav Target , ( 2000 ) 8 ( 2 ) : 107-17 . ioral, biochemical and neuroendocrine effects of neuroleptics in the Dange et al. , Comparison of Biovailability and Pharmacodynamics rat : potential treatment of extrapyramidal side effects .Neuropharmacol of Dillndian J Physiol Pharmacol. , ( 1992 ) 36 ( 3 ) :205-208 . ogy ( 1993 ) 32 ( 10 ) : 1037-1045 . [Farmacia Práctica Remington vol. 2 , 17 Ed. Editorial Medica Svensson T.H. et al. , Effects of 5 -HT2- and DA - D2 - receptor antago Panamericana , Capitulo VIII , Preparados Farmacéuticos y su nists on the mesolimbocortical DA system assessed by electrophysiol Elaboración ] (pp . 2223-2229 ) . ogy and microdialysis . Schizophrenia Res . ( 1993 ) 9 (2,3 ) : 253. Filip et al. , Treatment of extrapyramidal side effects with terguride. International Search Report dated Apr. 29 , 2005 for International Psychiatry Res . ( 1992 ) 41 ( 1 ) : 9-16 . Application No. PCT /US2004 /036013 . Glenn et al ., Twenty years of pharmacology , J Head Trauma Office Action dated May 7 , 2015 in corresponding Argentine Patent Rehabil . (2005 ) 20 ( 1 ): 51-61 . Application No. P040103986 . Gordon et al ., In vivo and in vitro evaluation of four different Windholz et al . [Eds . ), The Merk Index - An Encyclopedia of aqueous polymeric dispersions for producing an enteric coated Chemicals , Drugs, and Biologicals , 10th Edition , No. 4480, pp . tablet , Int'l J Pharma. ( 1995 ) 115 ( 1 ) : 29-34 . 662/663 . US 10,463,648 B2 1 2 SUSTAINED RELEASE PHARMACEUTICAL COMPOSITIONS I R3 R4 INCORPORATION BY REFERENCE TO ANY 5 - PRIORITY APPLICATIONS HN ( CH2) n - Z Any and all applications for which a foreign or domestic R2 priority claim is identified in the Application Data Sheet as filed with the present application are hereby incorporated by 10 R1 reference under 37 CFR 1.57 . wherein : This application is a continuation of U.S. patent applica R and R² are , independently , hydrogen , alkyl of 1 to 6 tion Ser. No. 15 / 912,438 , entitled “ SUSTAINED RELEASE carbon atoms, phenyl or benzyl; PHARMACEUTICAL COMPOSITIONS” and filed Mar. 5 , 15 or R. and R ?, taken together, are benzylidene optionally 2018 , which in turn is a divisional of U.S. patent application substituted with R as defined below or alkylidene of up to Ser. No. 10 / 975,254 , entitled “ SUSTAINED RELEASE 6 carbon atoms; PHARMACEUTICAL COMPOSITIONS ” and filed Oct. or R and R ?, taken together with the carbon to which they 28 , 2004 , which in turn claims priority to U.S. Provisional are attached , form a carbonyl moiety or a cycloalkyl group Application No. 60 /515,315 , filed Oct. 29, 2003 , which is 20 having three to 6 carbon atoms ; incorporated herein by reference in its entirety . R * is hydrogen , hydroxy , halo , trifluoromethyl, trifluo romethoxy , alkyl of 1 to 6 carbon atoms, alkoxy of 1 to 6 BACKGROUND OF THE INVENTION carbon atoms, arylalkoxy of 7 to 12 carbon atoms, alkanoy loxy of 2 to 6 carbon atoms, amino ,mono- or di- alkylamino 25 in which each alkyl group has 1 to 6 carbon atoms, alkana Field of the Invention mido of 2 to 6 carbon atoms or alkanesulfonamido of 1 to 6 carbon atoms; This invention relates to sustained release formulations of R4 is hydrogen or alkyl of 1 to 6 carbon atoms; dopaminergic compounds , including S - 2 - [ ( Benzylamino ) n is one of the integers 0 , 1 , 2 , 3 , 4 , 5 , or 6 ; methyl) -2,3,8,9 -tetrahydro - 7H - 1,4 -dioxino [2,3 - e ]indol - 8 30 Z is hydrogen , hydroxy, alkyl of 1 to 6 carbon atoms, one ( aplindore) and pharmaceutically acceptable salts alkenyl of 2 to 6 carbon atoms, alkynyl of 2 to 6 carbon thereof. atoms, alkoxy of 1 to 6 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, polycyclic alkyl of 7 to 15 carbon atoms, phenyl optionally substituted with R3 as defined above , Description of the Related Art 35 phenoxy optionally substituted with R3 as defined above, naphthyl optionally substituted with R3 as defined above or Compounds having the 2-( Aminomethyl) -2,3,8,9-7H - 4 naphthyloxy optionally substituted with R3as defined above , dioxino[ 2,3 - e ] -indol - 8 - one structure have been reported to heteroaryl or heteroaryloxy, in which the heterocyclic ring of have significant activity at the dopamine receptor, as well as the heteroaryl or heteroaryloxy group is selected from the ability to modulate dopamine synthesis .
Load more

Recommended publications
  • Xenoport Hurt by Solzira NDA Withdrawal
    November 11, 2008 Xenoport hurt by Solzira NDA withdrawal Evaluate Vantage News that Xenoport and partner GlaxoSmithKline’s recent application for restless legs syndrome (RLS) drug Solzira will have to be withdrawn, with the FDA requesting that data from a single trial be re-formatted, caused Xenoport’s shares to fall 13% yesterday to a new 18-month low of $34.44. With a potential 4-6 month delay to approval and the postponement of a $23m milestone that Xenoport was due to receive from Glaxo on the FDA’s acceptance of Solzira’s NDA, senior executives at the specialty US company could be forgiven for feeling somewhat aggrieved with Glaxo for this apparent oversight, given the pharma giant’s supposed experience and expertise in regulatory filings. The setback to Solzira and resulting slump in Xenoport’s share price suggests that shareholders who have not fled the stock will be even more desperate for positive phase IIb data for GERD treatment, XP19986 (Event - XenoPort looking for end of year trial lift, October 10, 2008). Formatting issues Avoiding these kinds of regulatory pitfalls, after all the cost and hard work involved in taking a drug through clinical development, is becoming an increasingly important factor behind a company’s decision to sign up a big pharma partner in today’s tougher regulatory environment. Both companies were naturally keen to stress that the NDA withdrawal has nothing to do with the content of the filing, which probably makes the rejection on a technicality all the more frustrating for Xenoport. Whilst the FDA requested the data from one particular study to be re-formatted, Glaxo has decided to review the formatting of other data sets in the application, presumably to ensure there can be no further grounds for rejection.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]
  • Serotonin Dopamine Antagonists)
    NewNew DevelopmentsDevelopments inin thethe ResearchResearch andand TreatmentTreatment ofof SchizophreniaSchizophrenia StephenStephen M.M. Stahl,Stahl, MD,MD, PhDPhD Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine Sponsored by Neuroscience Education Institute Additionally sponsored by American Society for the Advancement of Pharmacotherapy This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP; Cephalon, Inc.; and Shire Pharmaceuticals Inc. with additional support from Alkermes, Inc.; Eli Lilly and Company; Jazz Pharmaceuticals, Inc.; and Sepracor Inc. Copyright © 2007 Neuroscience Education Institute. All rights reserved. Learning Objectives After completion of this lecture you should be able to: • Evaluate evidence about the function and efficacy of the newest antipsychotics • Describe the rationale and present state of pharmacogenetics research • Discuss goals and challenges of pharmacogenetics in psychiatry Copyright © 2008 Neuroscience Education Institute. All rights reserved. Overview: Four Bedtime Stories • A Tale of Serotonin Antagonism • The Dopamine Partial Agonism Story • Pharmacogenetics and the Genes • Once Upon a Glutamate Receptor Copyright © 2008 Neuroscience Education Institute. All rights reserved. Overview: Four Bedtime Stories • A Tale of Serotonin Antagonism • The Dopamine Partial Agonism Story • Pharmacogenetics and the Genes • Once Upon a Glutamate Receptor Copyright © 2008 Neuroscience Education Institute. All rights reserved. What
    [Show full text]
  • 2009 Paris, France the Movement Disorder Society’S 13Th International Congress of Parkinson’S Disease and Movement Disorders
    FINAL PROGRAM The Movement Disorder Society’s 13th International Congress OF PARKINSon’S DISEASE AND MOVEMENT DISORDERS JUNE 7-11, 2009 Paris, France The Movement Disorder Society’s 13th International Congress of Parkinson’s Disease and Movement Disorders Claiming CME Credit To claim CME credit for your participation in the MDS 13th International Congress of Parkinson’s Disease and Movement Disorders, International Congress participants must complete and submit an online CME Request Form. This Form will be available beginning June 10. Instructions for claiming credit: • After June 10, visit www.movementdisorders.org/congress/congress09/cme • Log in following the instructions on the page. You will need your International Congress Reference Number, located on the upper right of the Confirmation Sheet found in your registration packet. • Follow the on-screen instructions to claim CME Credit for the sessions you attended. • You may print your certificate from your home or office, or save it as a PDF for your records. Continuing Medical Education The Movement Disorder Society is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation The Movement Disorder Society designates this educational activity for a maximum of 30.5 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity. Non-CME Certificates of Attendance were included with your on- site registration packet. If you did not receive one, please e-mail [email protected] to request one. The Movement Disorder Society has sought accreditation from the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Downloaded from Survive Nursing | Survivenursing.Com V20110426
    Generic Stem Stem Definition Examples -abine (see -arabine, -citabine) decitabine -ac Anti-inflammatory agents (acetic acid derivatives) bromfenac; dexpemedolac -acetam See -racetam -actide Synthetic corticotropins seractide -adol or -aldol- Analgesics (mixed opiate receptor agonists/ antagonists) tazadolene; spiradolene; levonantradol -adox Antibacterials (quinoline dioxide derivatives) carbadox -afenone Antiarrhythmics (propafenone derivatives) alprafenone; diprafenone -afil PDE5 inhibitors tadalafil -aj- Antiarrhythmics (ajmaline derivatives) lorajmine -aldrate Antacid aluminum salts magaldrate -algron Alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol Combined alpha and beta blockers labetalol; medroxalol -amivir (see -vir) -ampa Ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) -ampanel Ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) ; becampanel antagonists -ampator Ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) ; forampator modulators -andr- Androgens nandrolone -anib Angiogenesis inhibitors semaxanib -anserin Serotonin 5-HT2 receptor antagonists altanserin; tropanserin; adatanserin -antel Anthelmintics (undefined group) carbantel -antrone Antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine Antineoplastics (arabinofuranosyl derivatives) fazarabine; fludarabine aril-, -aril, -aril- Antiviral (arildone derivatives) pleconaril; arildone; fosarilate -arit Antirheumatics (lobenzarit type) lobenzarit; clobuzarit -arol
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2016/0220580 A1 Rubin Et Al
    US 2016O220580A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2016/0220580 A1 Rubin et al. (43) Pub. Date: Aug. 4, 2016 (54) SMALL MOLECULESCREENING FOR (60) Provisional application No. 61/497,708, filed on Jun. MOUSE SATELLITE CELL PROLIFERATION 16, 2011. (71) Applicant: PRESIDENT AND FELLOWS OF Publication Classification HARVARD COLLEGE, Cambridge, (51) Int. Cl. MA (US) A 6LX3/553 (2006.01) (72) Inventors: Lee L. Rubin, Wellesley, MA (US); A613 L/496 (2006.01) Amanda Gee, Alexandria, VA (US); A613 L/4439 (2006.01) Amy J. Wagers, Cambridge, MA (US) A613 L/404 (2006.01) (52) U.S. Cl. CPC ............. A6 IK3I/553 (2013.01); A61 K3I/404 (21) Appl. No.: 15/012,656 (2013.01); A61 K3I/496 (2013.01); A61 K 31/4439 (2013.01) (22) Filed: Feb. 1, 2016 (57) ABSTRACT The invention provides methods for inducing, enhancing or Related U.S. Application Data increasing satellite cell proliferation, and an assay for screen (63) Continuation-in-part of application No. 14/126,716, ing for a candidate compound for inducing, enhancing or filed on Jun. 13, 2014, now Pat. No. 9.248,185, filed as increasing satellite cell proliferation. Also provided are meth application No. PCT/US2012/042964 on Jun. 18, ods for repairing or regenerating a damaged muscle tissue of 2012. a Subject. Patent Application Publication Aug. 4, 2016 Sheet 1 of 44 US 2016/0220580 A1 FIG. A Patent Application Publication Aug. 4, 2016 Sheet 2 of 44 US 2016/0220580 A1 FIG. C. FIG. 2A Patent Application Publication Aug.
    [Show full text]
  • Novel Therapeutic Strategies in Parkinson's Disease
    Novel therapeutic strategies in Parkinson’s disease Peter Klivenyi, Laszlo Vecsei To cite this version: Peter Klivenyi, Laszlo Vecsei. Novel therapeutic strategies in Parkinson’s disease. European Journal of Clinical Pharmacology, Springer Verlag, 2009, 66 (2), pp.119-125. 10.1007/s00228-009-0742-4. hal-00535002 HAL Id: hal-00535002 https://hal.archives-ouvertes.fr/hal-00535002 Submitted on 11 Nov 2010 HAL is a multi-disciplinary open access L’archive ouverte pluridisciplinaire HAL, est archive for the deposit and dissemination of sci- destinée au dépôt et à la diffusion de documents entific research documents, whether they are pub- scientifiques de niveau recherche, publiés ou non, lished or not. The documents may come from émanant des établissements d’enseignement et de teaching and research institutions in France or recherche français ou étrangers, des laboratoires abroad, or from public or private research centers. publics ou privés. Eur J Clin Pharmacol (2010) 66:119–125 DOI 10.1007/s00228-009-0742-4 REVIEW ARTICLE Novel therapeutic strategies in Parkinson’s disease Peter Klivenyi & Laszlo Vecsei Received: 30 June 2009 /Accepted: 30 September 2009 /Published online: 16 October 2009 # Springer-Verlag 2009 Introduction producing symptomatic benefit. However, in the subse- quent human clinical trials, many of them failed to produce Parkinson’s disease (PD) is a neurodegenerative disorder the same efficacy as seen in preclinical studies. These characterized by resting tremor, rigidity, and bradykinesia. failures are not necessarily an indication of drug failure or The pathological processes begin years/decades before the drug action but may be related to inadequate administration, first motor symptoms are observed.
    [Show full text]
  • Wo 2007/075896 A2
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date PCT (10) International Publication Number 5 July 2007 (05.07.2007) WO 2007/075896 A2 (51) International Patent Classification: Arrow Rock Avenue, San Diego, CA 92126 (US). LUM, A61K 31/501 (2006.01) C07D 417/02 (2006.01) Christopher [US/US]; 13384 Bavarian Drive, San Diego, CA 92129 (US). ERNST, Justin [US/US]; 3535 Lebon (21) International Application Number: Drive #5105, San Diego, CA 92122 (US). PCT/US2006/048803 (74) Agents: CARSTEN, Douglas, H. et al; FOLEY & (22) International Filing Date: LARDNER LLP, P.O. Box 80278, San Diego, CA 20 December 2006 (20.12.2006) 92138-0278 (US). (25) Filing Language: English (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT,AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, (26) Publication Language: English CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, (30) Priority Data: JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, 60/753,634 22 December 2005 (22.12.2005) US LT, LU, LV,LY,MA, MD, MG, MK, MN, MW, MX, MY, 60/787,362 30 March 2006 (30.03.2006) US MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, 60/842,051 1 September 2006 (01.09.2006) US RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW (71) Applicant (for all designated States except US): KEMIA, INC.
    [Show full text]
  • OMED 17 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME Credits Anticipated
    ® OCTOBER 7 - 10 OMED 17 PHILADELPHIA, PENNSYLVANIA 29.5 Category 1-A CME credits anticipated ACOFP / AOA’s 122nd Annual Osteopathic Medical Conference & Exposition Joint Session with ACOFP and Cleveland Clinic: Managing Chronic Disease Parkinson's Disease: Early Warning Signs, When to Refer Hubert Fernandez, MD The American College of Osteopathic Family Physicians is accredited by the American Osteopathic Association Council to sponsor continuing medical education for osteopathic physicians. The American College of Osteopathic Family Physicians designates the lectures and workshops for Category 1-A credits on an hour-for-hour basis, pending approval by the AOA CCME, ACOFP is not responsible for the content. 10/5/2017 Early (and Late) Signs of PD: When to Refer Hubert H. Fernandez, MD, FAAN, FANA Professor of Medicine (Neurology) Cleveland Clinic Lerner College of Medicine Center Director Center for Neurological Restoration, Cleveland Clinic Disclosures Consulting: AbbVie, Acadia, Eli Lilly, Indus, Ipsen, Merz, Novartis, Pfizer, Sunovion, Voyager Independent Contractor (including contracted research): Acordia, Biogen, Kyowa Hakko, Michael J Fox Foundation, NIH/NINDS, Parkinson Study Group, Rhythm, Teva Teaching and Speaking: Medscape, Vindico Education 1 10/5/2017 Who gets PD? . Mean age of onset: 60-70, M>F . Affects 0.3% of the population and 1% of those older than 60 . Over 1.5 million people in North America affected Nutt JG and Wooten GF. New Engl J Med 2005;353(10): 1021-1027 PD Motor Symptoms 2 10/5/2017 The Parkinson Family Essential Tremor Progressive Drugs Multi- Vascular Supranuclear System Palsy Atrophy Idiopathic Toxins Parkinson’s Parkinson- Other Secondary Disease plus Encephalitis Lewy Cortico Body Basal Alzheimer’s Other Disease Degeneration Disease A Brief History of Our Understanding of PD 1917 2017 paralysis 1817 agitans Goetz CG.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]